Story
CVS Outlook Raised to Positive by Moody's on Health Insurance Turnaround

Moody's Ratings has revised its outlook on CVS Health Corp. (NYSE:CVS) to positive from stable, signaling growing confidence in the company's financial trajectory. The ratings agency on Friday affirmed CVS's Baa3 senior unsecured notes, Ba1 junior subordinated notes, and Prime-3 commercial paper rating, pointing to a successful turnaround in its health insurance division.
Turnaround Efforts Drive Deleveraging
The outlook change is primarily driven by CVS's progress in deleveraging its balance sheet. Moody's noted that the company has effectively managed its health insurance business by pruning membership, adjusting pricing and benefit designs, and exiting the individual health insurance market.
These strategic moves have significantly improved the company's key credit metrics. Moody's estimates CVS's gross debt-to-EBITDA ratio stood at approximately 3.7x as of June 30, 2026. This marks a substantial reduction from a peak of 5.0x at the end of 2024 and 4.4x at year-end 2025.
Core Strengths and Lingering Risks
CVS's investment-grade Baa3 rating is underpinned by its substantial scale and market-leading positions across several key sectors. The company's strengths include:
Ad- Dominance in pharmacy benefit management (PBM), retail pharmacy, and health insurance.
- Favorable industry fundamentals, such as rising prescription drug utilization.
- Improved performance in its retail pharmacy operations, driven by a new reimbursement model.
Despite the positive outlook, Moody's highlighted persistent risks. The company continues to face industry-wide challenges and potential volatility within its health insurance operations, particularly in the Medicare Advantage segment. Furthermore, regulatory uncertainty looms over its PBM business practices following recent legislative reforms.
Path to an Upgrade
A future ratings upgrade is possible if CVS can demonstrate sustained operational strength across its key business segments while adhering to disciplined financial policies, according to Moody's. The agency specified that maintaining a debt-to-EBITDA ratio below 4.0x would be a key consideration for an upgrade. For the 12 months ended June 30, 2026, CVS reported total revenues of $415 billion.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.